Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 17, 2009

ChemDiv Purchases Prudentas to Strengthen Foothold in Eastern Europe

  • ChemDiv is expanding its CRO activities through the acquisition of Prudentas. ChemDiv believes that Prudentas’ range of services covering Phase I through Phase IV studies in Eastern Europe will add to its Discovery outSource™.

    “Our decision to make this investment capitalizes on the growing trend of conducting clinical trials in Eastern Europe based on the availability of naive patient populations, rapid and efficient trial recruitment, and high data quality across a broad range of therapeutic indications including CNS, cardiovascular and metabolic disorders, oncology, inflammation, and infectious disease; areas already covered by our Discovery outSource service,” explains Nikolay Savchuk, president and CEO of ChemDiv.

    ChemDiv previously worked with Prudentas in response to a growing partner base interested in conducting clinical trials. Now ChemDiv’s ChemRar High Tech Center will take over Prudentas. It will operate separately under the business name Prudentas LLC, a ChemDiv Group company.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »